R
Raj Patel
Researcher at Royal South Hants Hospital
Publications - 58
Citations - 1946
Raj Patel is an academic researcher from Royal South Hants Hospital. The author has contributed to research in topics: Valaciclovir & Transmission (medicine). The author has an hindex of 16, co-authored 56 publications receiving 1729 citations. Previous affiliations of Raj Patel include University of Southampton & Solent NHS Trust.
Papers
More filters
Journal ArticleDOI
Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes
Lawrence Corey,Anna Wald,Raj Patel,Stephen L. Sacks,Stephen K. Tyring,Terri Warren,John M. Douglas,Jorma Paavonen,R. Ashley Morrow,Karl R. Beutner,Leonid S. Stratchounsky,Gregory J. Mertz,Oliver N. Keene,Helen A. Watson,Dereck Tait,Mauricio Vargas-Cortes +15 more
TL;DR: Once-daily suppressive therapy with valacyclovir significantly reduces the risk of transmission of genital herpes among heterosexual, HSV-2-discordant couples.
Journal ArticleDOI
2014 European guideline on the management of syphilis
Michel Janier,V. Hegyi,Nicolas Dupin,Magnus Unemo,George-Sorin Tiplica,M Potočnik,P. French,Raj Patel +7 more
TL;DR: Syphilis remains a major public health problem in Europe (both in Eastern Europesince the 1990's and in Western Europe since the re‐emergence of the disease in the late 1990's‐early 2000's).
Journal ArticleDOI
2020 European guideline on the management of syphilis.
TL;DR: The 2020 edition of the European guideline on the management of syphilis is an update of the 2014 edition.
Journal ArticleDOI
Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group.
TL;DR: It is demonstrated that once daily valaciclovir (500 mg), is highly effective and well tolerated for the suppression of recurrent genital HSV infection.
Journal ArticleDOI
Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection.
TL;DR: In this paper, the authors investigated whether suppressive antiviral therapy improves health related quality of life in patients with recurrent genital herpes (RGHQoL) and found that after 3 months, there were significantly greater improvements in mean RGHqoL scores for all active treatment groups compared with placebo (p < 0.05).